W. Fraser Symmans

AI-derived tumor-infiltrating lymphocytes enhance the prediction of pathologic complete response in early-stage triple-negative breast cancer

This repository contains small image tiles of annotations curated from ARTEMIS biopsy slides - de-identified information from 26 patients with breast cancer, used for model development in the paper entitled with 'AI-Derived Tumor-Infiltrating Lymphocytes Enhance the Prediction of...

Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial

Strategies are needed to avoid chemotherapy in early stage HER2-positive (HER2 + ) breast cancer (BC). We conducted a neoadjuvant therapy trial with zanidatamab, a dual HER2-directed bispecific antibody, in patients with 1-3 cm, node-negative HER2 + BC. Primary endpoint was patho...